| __timestamp | Merus N.V. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 13774000 |
| Thursday, January 1, 2015 | 839656 | 22479000 |
| Friday, January 1, 2016 | 4478145 | 27388000 |
| Sunday, January 1, 2017 | 16432324 | 35610000 |
| Monday, January 1, 2018 | 11890871 | 49007000 |
| Tuesday, January 1, 2019 | 34110000 | 61139000 |
| Wednesday, January 1, 2020 | 35781000 | 68836000 |
| Friday, January 1, 2021 | 40896000 | 97592000 |
| Saturday, January 1, 2022 | 52200000 | 106903000 |
| Sunday, January 1, 2023 | 59836000 | 120998000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and Merus N.V. from 2014 to 2023. Over this period, Vericel Corporation's SG&A expenses surged by approximately 780%, reflecting its aggressive growth strategy. In contrast, Merus N.V. experienced a more moderate increase of around 1,450%, indicating a steady expansion approach.
By 2023, Vericel's SG&A expenses reached nearly double those of Merus, highlighting its significant investment in administrative and sales functions. This trend suggests Vericel's focus on scaling operations, while Merus maintains a balanced growth trajectory. These insights provide a window into the strategic priorities of these companies, offering valuable lessons for investors and industry analysts alike.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.